Alkem licenses technology from Harvard to treat ischemic injury and vascular diseases
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
Company expects strong organic growth in sales, EBITDA in 2022
The phosphine ligand is available on the kilo scale for the first time, providing scientists with a powerful solution for cross-coupling chemistry
State-of-the-art laboratory to support ingredient and specialty chemical innovation, product formulation application development and more sustainable solutions across Europe and beyond
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
Brazil has the 4th largest pet market in the world with an estimated market size of BRL 1.8 billion, growing annually at 16%
TruPharma has commenced commercial marketing of Sage's approved generic cartridge product
110 BDS graduates admitted in week one of the launch
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
Subscribe To Our Newsletter & Stay Updated